BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 27262102)

  • 1. Clinical and analytical performance of the PapilloCheck HPV-Screening assay using the VALGENT framework.
    Heard I; Cuschieri K; Geraets DT; Quint W; Arbyn M
    J Clin Virol; 2016 Aug; 81():6-11. PubMed ID: 27262102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical performance of the HPV-Risk assay on cervical samples in SurePath medium using the VALGENT-4 panel.
    Heideman DAM; Xu L; Hesselink AT; Doorn S; Ejegod DM; Pedersen H; Quint WGV; Bonde J; Arbyn M
    J Clin Virol; 2019 Dec; 121():104201. PubMed ID: 31629967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of the Roche Linear Array HPV Genotyping Test within the VALGENT framework.
    Xu L; Oštrbenk A; Poljak M; Arbyn M
    J Clin Virol; 2018 Jan; 98():37-42. PubMed ID: 29241150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the Clinical Performance of the HPV-Risk Assay Using the VALGENT-3 Panel.
    Polman NJ; Oštrbenk A; Xu L; Snijders PJF; Meijer CJLM; Poljak M; Heideman DAM; Arbyn M
    J Clin Microbiol; 2017 Dec; 55(12):3544-3551. PubMed ID: 29021152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical validation of the Cobas 4800 HPV assay using cervical samples in SurePath medium under the VALGENT4 framework.
    Ejegod DM; Hansen M; Christiansen IK; Pedersen H; Quint W; Xu L; Arbyn M; Bonde J
    J Clin Virol; 2020 Jul; 128():104336. PubMed ID: 32446166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance of a Cartridge-Based Assay for Detection of Clinically Significant Human Papillomavirus (HPV) Infection: Lessons from VALGENT (Validation of HPV Genotyping Tests).
    Cuschieri K; Geraets D; Cuzick J; Cadman L; Moore C; Vanden Broeck D; Padalko E; Quint W; Arbyn M
    J Clin Microbiol; 2016 Sep; 54(9):2337-42. PubMed ID: 27385707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and Analytical Performance of the Onclarity HPV Assay Using the VALGENT Framework.
    Cuschieri K; Geraets DT; Moore C; Quint W; Duvall E; Arbyn M
    J Clin Microbiol; 2015 Oct; 53(10):3272-9. PubMed ID: 26246482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening?
    Arbyn M; Snijders PJ; Meijer CJ; Berkhof J; Cuschieri K; Kocjan BJ; Poljak M
    Clin Microbiol Infect; 2015 Sep; 21(9):817-26. PubMed ID: 25936581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VALGENT: A protocol for clinical validation of human papillomavirus assays.
    Arbyn M; Depuydt C; Benoy I; Bogers J; Cuschieri K; Schmitt M; Pawlita M; Geraets D; Heard I; Gheit T; Tommasino M; Poljak M; Bonde J; Quint W
    J Clin Virol; 2016 Mar; 76 Suppl 1():S14-S21. PubMed ID: 26522865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the clinical performance of PapilloCheck human papillomavirus detection with that of the GP5+/6+-PCR-enzyme immunoassay in population-based cervical screening.
    Hesselink AT; Heideman DA; Berkhof J; Topal F; Pol RP; Meijer CJ; Snijders PJ
    J Clin Microbiol; 2010 Mar; 48(3):797-801. PubMed ID: 20042622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and Analytical Performance of the BD Onclarity HPV Assay with SurePath Screening Samples from the Danish Cervical Screening Program Using the VALGENT Framework.
    Bonde JH; Pedersen H; Quint W; Xu L; Arbyn M; Ejegod DM
    J Clin Microbiol; 2020 Jan; 58(2):. PubMed ID: 31723012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2020 list of human papillomavirus assays suitable for primary cervical cancer screening.
    Arbyn M; Simon M; Peeters E; Xu L; Meijer CJLM; Berkhof J; Cuschieri K; Bonde J; Ostrbenk Vanlencak A; Zhao FH; Rezhake R; Gultekin M; Dillner J; de Sanjosé S; Canfell K; Hillemanns P; Almonte M; Wentzensen N; Poljak M
    Clin Microbiol Infect; 2021 Aug; 27(8):1083-1095. PubMed ID: 33975008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and Analytical Evaluation of the Anyplex II HPV HR Detection Assay within the VALGENT-3 Framework.
    Oštrbenk A; Xu L; Arbyn M; Poljak M
    J Clin Microbiol; 2018 Nov; 56(11):. PubMed ID: 30209184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and analytical performance of the CLART HPV 4S assay with SurePath screening samples from the Danish cervical cancer screening program using the VALGENT framework.
    Ejegod DM; Pedersen H; Quint W; Xu L; Arbyn M; Bonde JH
    J Virol Methods; 2021 Jun; 292():114118. PubMed ID: 33766660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical performance of the novel full-genotyping OncoPredict HPV Quantitative Typing assay using the VALGENT framework.
    Cocuzza CE; Dhillon SK; Martinelli M; Giubbi C; Njoku RC; Bhatia R; Cuschieri K; Arbyn M
    Int J Cancer; 2024 Feb; 154(3):538-547. PubMed ID: 37855030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Head-to-Head Analytical Comparison of Cobas 4800 HPV, PapilloCheck HPV Screening, and LMNX Genotyping Kit HPV GP for Detection of Human Papillomavirus DNA in Cervical and Cervicovaginal Swabs.
    Jaworek H; Koudelakova V; Drabek J; Vrbkova J; Zborilova B; Oborna I; Brezinova J; Marek R; Huml K; Vanek P; Hajduch M
    J Mol Diagn; 2018 Nov; 20(6):849-858. PubMed ID: 30165205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the PapilloCheck DNA micro-array Human Papillomavirus detection assay with Hybrid Capture II and PCR-enzyme immunoassay using the GP5/6+ primer set.
    Jones J; Powell NG; Tristram A; Fiander AN; Hibbitts S
    J Clin Virol; 2009 Jun; 45(2):100-4. PubMed ID: 19394266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical evaluation of a GP5+/6+-based luminex assay having full high-risk human papillomavirus genotyping capability and an internal control.
    Geraets DT; Cuschieri K; de Koning MN; van Doorn LJ; Snijders PJ; Meijer CJ; Quint WG; Arbyn M
    J Clin Microbiol; 2014 Nov; 52(11):3996-4002. PubMed ID: 25210073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Evaluation of INNO-LiPA HPV Genotyping
    Xu L; Padalko E; Oštrbenk A; Poljak M; Arbyn M
    Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30208597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the clinical performance of OncoPredict HPV® SCR assay within the VALGENT-2 framework.
    Dhillon SK; Cocuzza CE; Chung PYJ; Martinelli M; Giubbi C; Njoku RC; Bhatia R; Cuschieri K; Arbyn M
    J Med Virol; 2023 Jan; 95(1):e28417. PubMed ID: 36541733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.